Hospital costs for patients with lower extremity cellulitis: a retrospective population-based study
- PMID: 28944703
- PMCID: PMC5935496
- DOI: 10.1080/21548331.2017.1384690
Hospital costs for patients with lower extremity cellulitis: a retrospective population-based study
Abstract
Objectives: Hospital admissions for non-purulent lower extremity cellulitis (NLEC) are common and can be prolonged and costly. Newer treatment options and preventive strategies are expected to result in cost savings before implementation, but few studies have quantified the cost of conventional treatment.
Methods: Using the Rochester Epidemiology Project, the incidence of NLEC in Olmsted County, MN in 2013 was 176.6 per 100,000 persons. The subset of patients who required hospitalization for NLEC in 2013 was determined. Hospital admissions were analyzed retrospectively using standardized cost analysis within several relevant categories.
Results: Thirty-four patients had an average hospital length of stay of 4.7 days. The median total inpatient cost was $7,341. The median cost per day was $2,087, with 49% due to room and board. Antibiotics administered for treatment of NLEC contributed a median cost of $75 per day of hospitalization, and laboratory and imaging test costs were $73 and $44, respectively, per day of hospitalization.
Conclusion: Hospitalizations for NLEC can be costly and prolonged with room and board accounting for much of the cost. Therefore, newer management strategies should seek to reduce hospital length of stay and/or avoid inpatient admission to reduce cost.
Keywords: Lower extremity cellulitis; Rochester epidemiology project; cost; hospitalization; inpatient; population-based.
Conflict of interest statement
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Figures
Similar articles
-
Hospital cost analysis of children with preseptal cellulitis.Int J Pediatr Otorhinolaryngol. 2018 Mar;106:96-99. doi: 10.1016/j.ijporl.2018.01.007. Epub 2018 Feb 2. Int J Pediatr Otorhinolaryngol. 2018. PMID: 29447901
-
Economic burden of hospital admissions for patients with acute bacterial skin and skin structure infections in the United States.Hosp Pract (1995). 2018 Dec;46(5):278-286. doi: 10.1080/21548331.2018.1506673. Epub 2018 Aug 21. Hosp Pract (1995). 2018. PMID: 30067108
-
Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting.J Med Econ. 2015;18(12):1092-101. doi: 10.3111/13696998.2015.1078339. Epub 2015 Sep 14. J Med Econ. 2015. PMID: 26368787
-
Analysis of Readmissions Following Hospitalization for Cellulitis in the United States.JAMA Dermatol. 2019 Jun 1;155(6):720-723. doi: 10.1001/jamadermatol.2018.4650. JAMA Dermatol. 2019. PMID: 30810708 Free PMC article.
-
Global hospital and operative costs associated with various ventral cavity procedures: a comprehensive literature review and analysis across regions.J Med Econ. 2019 Nov;22(11):1210-1220. doi: 10.1080/13696998.2019.1661680. Epub 2019 Sep 14. J Med Econ. 2019. PMID: 31456454
Cited by
-
Cost-effectiveness and value of information analyses of Bruton's tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States.J Manag Care Spec Pharm. 2022 Apr;28(4):390-400. doi: 10.18553/jmcp.2022.28.4.390. J Manag Care Spec Pharm. 2022. PMID: 35332792 Free PMC article.
-
The critical role of phlebolymphedema in cellulitis associated with lymphedema: Its incidence and economic impact in a large real-world population.J Vasc Surg Venous Lymphat Disord. 2024 Mar;12(2):101704. doi: 10.1016/j.jvsv.2023.101704. Epub 2023 Nov 17. J Vasc Surg Venous Lymphat Disord. 2024. PMID: 37977518 Free PMC article.
-
Recurrent Cellulitis: Who is at Risk and How Effective is Antibiotic Prophylaxis?Int J Gen Med. 2022 Aug 10;15:6561-6572. doi: 10.2147/IJGM.S326459. eCollection 2022. Int J Gen Med. 2022. PMID: 35983462 Free PMC article. Review.
-
Compression Therapy Is Cost-Saving in the Prevention of Lower Limb Recurrent Cellulitis in Patients with Chronic Edema.Lymphat Res Biol. 2023 Apr;21(2):160-168. doi: 10.1089/lrb.2022.0029. Epub 2022 Aug 23. Lymphat Res Biol. 2023. PMID: 35997601 Free PMC article. Clinical Trial.
-
Diagnosis and treatment of the invasive extension of bacteria (cellulitis) from chronic wounds utilising point-of-care fluorescence imaging.Int Wound J. 2022 Aug;19(5):996-1008. doi: 10.1111/iwj.13696. Epub 2021 Oct 5. Int Wound J. 2022. PMID: 34609047 Free PMC article.
References
-
- McNamara DR, et al. Incidence of lower-extremity cellulitis: a population-based study in Olmsted county, Minnesota. Mayo Clin Proc. 2007;82(7):817–21. - PubMed
-
- Kameshwar K, et al. False economies in home-based parenteral antibiotic treatment: a health-economic case study of management of lower-limb cellulitis in Australia. J Antimicrob Chemother. 2016;71(3):830–5. - PubMed
-
- Stevens DL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014;59(2):147–59. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical